Evotec SE — Board/Management Information 2002

Dec 9, 2002

News Details

Ad-hoc | 9 December 2002 08:49

Evotec OAI AG english

Evotec OAI Appoints Ian Hunneyball as a Member of the Management Board Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Evotec OAI AG (WKN 566480) announced today the appointment of Ian M. Hunneyball as President of Discovery Services, the Company’s core business, and a member of its Management Board. He will lead Evotec OAI’s chemistry operations in Abingdon, UK, and the biology services operations in Hamburg, Germany. Evotec OAI has created this position as a consequence of increasing demand for integrated “Target-to-IND-Services” covering all biology and chemistry aspects of drug discovery. Dr Hunneyball, 52, will join Evotec OAI with effect from January 1, 2003. He brings more than 24 years’ of business experience in the pharmaceutical and biotech industry to the company. Most recently, Dr. Hunneyball was Director of R&D at Entomed S.A., a French biotechnology company involved in the discovery and development of drugs derived from the biology of insects. He joined Knoll Pharmaceuticals Ltd. (BASF Pharma) in 1995, where he was Director of Research and Development. During his six years at Knoll he was responsible for all UK R&D activities. He oversaw the global development of two new chemical entities (flosequinan, sibutramine) from discovery through to registration. Dr Hunneyball has a Ph.D in medical biochemistry from the University of Birmingham, England. The company also announced today that Sean Marett, 37, currently Chief Business Officer, will become Senior Vice President, Licensing and Negotiations, with effect from January 1, 2003, with responsibility for negotiating the Company’s high-level partnership agreements. In his new position, he will no longer be member of the Management Board. Contact: Anne Hennecke, Evotec OAI AG, Investor Relations, phone: +49/40/56081- 286, e-mail: anne.hennecke@evotecoai.com end of ad-hoc-announcement (c)DGAP 09.12.2002 ——————————————————————————– WKN: 566480; ISIN: DE0005664809; Index: NEMAX-50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 090849 Dez 02